Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B3c39deec1545970baa7b51bd84eebc82> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B3c39deec1545970baa7b51bd84eebc82 NCIT_P378 "NCI" @default.
- B3c39deec1545970baa7b51bd84eebc82 type Axiom @default.
- B3c39deec1545970baa7b51bd84eebc82 annotatedProperty IAO_0000115 @default.
- B3c39deec1545970baa7b51bd84eebc82 annotatedSource NCIT_C180596 @default.
- B3c39deec1545970baa7b51bd84eebc82 annotatedTarget "A preparation of autologous CD4/CD8 enriched T-lymphocytes engineered to express pLTG1497, a tandem chimeric antigen receptor (CAR) specific for the two tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19) and CD20, with potential immunostimulating and antineoplastic activities. Upon administration, zamtocabtagene autoleucel target and bind to CD19- and CD20-expressing tumor B-cells. This induces selective toxicity in tumor B-cells expressing these TAAs. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies. Targeting both CD19 and CD20 may prevent tumor cell antigen escape and relapse." @default.